Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Motor neurone disease: progress and challenges.
Dharmadasa T, Henderson RD, Talman PS, Macdonell RA, Mathers S, Schultz DW, Needham M, Zoing M, Vucic S, Kiernan MC. Dharmadasa T, et al. Among authors: mathers s. Med J Aust. 2017 May 1;206(8):357-362. doi: 10.5694/mja16.01063. Med J Aust. 2017. PMID: 28446118 Review.
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, Rowe D, Schultz D, Edis R, Needham M, Macdonnell R, McCombe P, Birks C, Kiernan M. Talman P, et al. Among authors: mathers s. BMJ Open. 2016 Sep 30;6(9):e012054. doi: 10.1136/bmjopen-2016-012054. BMJ Open. 2016. PMID: 27694488 Free PMC article.
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, Nath A, Garcia Montojo M, Norato G, Santamaria UA, Rogers ML, Malaspina A, Lombardi V, Mehta PR, Westeneng HJ, van den Berg LH, Al-Chalabi A. Gold J, et al. Among authors: mathers s. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):595-604. doi: 10.1080/21678421.2019.1632899. Epub 2019 Jul 8. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31284774
Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
Vucic S, Ryder J, Mekhael L, Rd H, Mathers S, Needham M, Dw S, Mc K; TEALS study group. Vucic S, et al. Among authors: mathers s. Medicine (Baltimore). 2020 Feb;99(6):e18904. doi: 10.1097/MD.0000000000018904. Medicine (Baltimore). 2020. PMID: 32028398 Free PMC article.
Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis.
Nabais MF, Lin T, Benyamin B, Williams KL, Garton FC, Vinkhuyzen AAE, Zhang F, Vallerga CL, Restuadi R, Freydenzon A, Zwamborn RAJ, Hop PJ, Robinson MR, Gratten J, Visscher PM, Hannon E, Mill J, Brown MA, Laing NG, Mather KA, Sachdev PS, Ngo ST, Steyn FJ, Wallace L, Henders AK, Needham M, Veldink JH, Mathers S, Nicholson G, Rowe DB, Henderson RD, McCombe PA, Pamphlett R, Yang J, Blair IP, McRae AF, Wray NR. Nabais MF, et al. Among authors: mathers s. NPJ Genom Med. 2020 Feb 27;5:10. doi: 10.1038/s41525-020-0118-3. eCollection 2020. NPJ Genom Med. 2020. PMID: 32140259 Free PMC article.
67 results